These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 22615013)

  • 21. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.
    Lin SM; Yang SH; Liang CC; Huang HK
    Osteoporos Int; 2018 Jan; 29(1):153-162. PubMed ID: 29032384
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of fracture risk between proton pump inhibitors and histamine-2 receptor antagonists in ANCA-associated vasculitis patients: a nested case-control study.
    Miyano S; Michihata N; Sada KE; Uda K; Matsui H; Fushimi K; Nangaku M; Yasunaga H
    Rheumatology (Oxford); 2021 Apr; 60(4):1717-1723. PubMed ID: 33067623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial.
    Kendler DL; Marin F; Geusens P; López-Romero P; Lespessailles E; Body JJ; Minisola S
    Bone; 2020 Jan; 130():115113. PubMed ID: 31654779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study.
    Prieto-Alhambra D; Pagès-Castellà A; Wallace G; Javaid MK; Judge A; Nogués X; Arden NK; Cooper C; Diez-Perez A
    J Bone Miner Res; 2014 Jan; 29(1):268-74. PubMed ID: 23761350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of proton pump inhibitors and risk of osteoporosis-related fractures.
    Targownik LE; Lix LM; Metge CJ; Prior HJ; Leung S; Leslie WD
    CMAJ; 2008 Aug; 179(4):319-26. PubMed ID: 18695179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fracture risk in hepatitis C virus infected persons: results from the DANVIR cohort study.
    Hansen AB; Omland LH; Krarup H; Obel N;
    J Hepatol; 2014 Jul; 61(1):15-21. PubMed ID: 24650694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors.
    Roux C; Goldstein JL; Zhou X; Klemes A; Lindsay R
    Osteoporos Int; 2012 Jan; 23(1):277-84. PubMed ID: 21365461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Osteoporosis or fracture risk associated with thiazolidinedione and proton pump inhibitor co-administration in patients with type 2 diabetes mellitus.
    Ock M; Lee S; Kim H
    J Clin Pharm Ther; 2022 Jul; 47(7):1028-1035. PubMed ID: 35257383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proton pump inhibitor use is associated with hip fracture development: a nationwide population-based cohort study.
    Min YW; Lee YC; Kim K; Ryu S; Hong KS; Jeon HH; Kim YS; Park JH; Son HJ; Rhee PL
    Korean J Intern Med; 2020 Sep; 35(5):1084-1093. PubMed ID: 31671930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden.
    Brusselaers N; Wahlin K; Engstrand L; Lagergren J
    BMJ Open; 2017 Oct; 7(10):e017739. PubMed ID: 29084798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term proton pump inhibitor use and risk of osteoporosis and hip fractures: A nationwide population-based and multicenter cohort study using a common data model.
    Park DH; Seo SI; Lee KJ; Kim J; Kim Y; Seo WW; Lee HS; Shin WG; Yoo JJ
    J Gastroenterol Hepatol; 2022 Aug; 37(8):1534-1543. PubMed ID: 35501296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early Acid Suppression Therapy Exposure and Fracture in Young Children.
    Malchodi L; Wagner K; Susi A; Gorman G; Hisle-Gorman E
    Pediatrics; 2019 Jul; 144(1):. PubMed ID: 31175146
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study.
    Moberg LM; Nilsson PM; Samsioe G; Borgfeldt C
    Maturitas; 2014 Aug; 78(4):310-5. PubMed ID: 24958166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fracture risk and bone mineral density reduction associated with proton pump inhibitors.
    Lau YT; Ahmed NN
    Pharmacotherapy; 2012 Jan; 32(1):67-79. PubMed ID: 22392829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies.
    Poly TN; Islam MM; Yang HC; Wu CC; Li YJ
    Osteoporos Int; 2019 Jan; 30(1):103-114. PubMed ID: 30539272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
    Chandrasekhar J; Bansilal S; Baber U; Sartori S; Aquino M; Farhan S; Vogel B; Faggioni M; Giustino G; Ariti C; Colombo A; Chieffo A; Kini A; Saporito R; Michael Gibson C; Witzenbichler B; Cohen D; Moliterno D; Stuckey T; Henry T; Pocock S; Dangas G; Gabriel Steg P; Mehran R
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):E217-E225. PubMed ID: 27650638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study.
    Freedberg DE; Haynes K; Denburg MR; Zemel BS; Leonard MB; Abrams JA; Yang YX
    Osteoporos Int; 2015 Oct; 26(10):2501-7. PubMed ID: 25986385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reported proton pump inhibitor side effects: what are physician and patient perspectives and behaviour patterns?
    Ghosh G; Schnoll-Sussman F; Mathews S; Katz PO
    Aliment Pharmacol Ther; 2020 Jan; 51(1):121-128. PubMed ID: 31664732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative.
    Gray SL; LaCroix AZ; Larson J; Robbins J; Cauley JA; Manson JE; Chen Z
    Arch Intern Med; 2010 May; 170(9):765-71. PubMed ID: 20458083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos).
    Targownik LE; Leslie WD; Davison KS; Goltzman D; Jamal SA; Kreiger N; Josse RG; Kaiser SM; Kovacs CS; Prior JC; Zhou W;
    Am J Gastroenterol; 2012 Sep; 107(9):1361-9. PubMed ID: 22777336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.